Invasive fungal infections in the immunocompromised host: recent advances in diagnosis, treatment and prevention  by Bouza, Emilio
INTRODUCTION
Invasive fungal infections in the immunocompromised host: recent
advances in diagnosis, treatment and prevention
Emilio Bouza
Professor of Medical Microbiology, Hospital Gregorio Maran˜o´n, University of Madrid,
Madrid, Spain
Undoubtedly, one of the most innovative ﬁelds in
infectious diseases is that concerning invasive my-
cosis causedbyﬁlamentous fungi.Thekeywordhere
could be ‘change’—change in the patientswho suffer
from these infections, in the causal fungi, in our
approach to thecondition, in thedrugsweuse to treat
these infections, and in the need to prevent them.
This issue reviews different aspects of mycosis,
particularly those infections caused by fungi of
the genus Aspergillus and the Mucoraceae family,
which are currently the most important agents to
be treated and prevented in patients suffering
from severe immunodepression.
In this issue, Miguel Angel Sanz, Head of the
Haematology Service at Hospital La Fe in Valen-
cia, reviews the epidemiology of invasive
mucormycosis and aspergillosis during the last
few years, using data from his own institution. In
the following study, Patricia Mun˜oz from the
Hospital Gregorio Maran˜o´n in Madrid brings us
up to date with the most recent data on the
clinical presentation of invasive aspergillosis and
classiﬁes the diagnostic procedures available.
The issue also includes an article on mucormy-
cosis, a disease with recent changes in incidence
both in the USA and in Europe, where there has
been widespread use of antifungal drugs that are
not active against mucorales in the prophylaxis of
invasive mycosis caused by ﬁlamentous fungi.
This situation is not common in most European
hospitals. Therefore, we should plan carefully for
the re-emergence of mucormycosis.
GuillermoQuindo´s fromtheUniversidaddelPaı´s
Vasco in Bilbao, who has a very wide experience in
the ﬁeld, reviews the new microbiological diagnos-
tic techniques available and their immediate future.
This supplement also includes an in-depth
review by Jose´ Miguel Cisneros, from the Hospital
Virgen del Rocı´o in Sevilla, on the systemic use of
currently available antifungal drugs as well as
their indications and limitations.
Given the incidence and high mortality rate of
mycosis in patients with malignant haematological
tumours, we feel that it is essential to devote one
article to prevention, using antifungal drugs in this
context. This is undertaken by Rafael de la Ca´mara,
expert in haematological infections at theHaematol-
ogy Service of theHospital de la Princesa inMadrid.
Prevention of exposure receives little attention.
Nevertheless, this essential area is covered magis-
terially in the review by Enric Carreras, from the
Haematology Service of the Hospital Clinic i
Provincial in Barcelona.
The last part of the issue reviews the contribution
made by itraconazole in the prevention and treat-
ment of invasive mycosis in neutropenic patients,
and discussesmonitoring in the hospital setting.We
contrastexperience inEuropeandtheUSA,with two
magniﬁcent reviews, one byAxel Glasmacher, from
the Department of Internal Medicine at the Bonn
Medizinische Klinik in Germany, and another by
DrewWinston, from the Department ofMedicine at
the UCLA Medical Center in Los Angeles, Califor-
nia. Both offer excellent ﬁrst-hand insight into the
existing data on the current role of itraconazole.
To conclude, Alfonso Domı´nguez-Gil Hurle´,
Professor of Pharmacy and Pharmaceutical Tech-
nology at the University of Salamanca in Spain,
reviews the interactions of itraconazole with other
drugs and the advantages of hospital monitoring.
Finally, I would like to say that this issue is the
result of the effort made by the pharmaceutical
company Esteve, Spain, which provided an unre-
stricted grant in order to bring together for a 1-day
session researchers interested in invasive mycosis
and its treatment, from theﬁelds ofmicrobiologyand
infectious diseases and medicine in general. We
believe that this supplement, which is a reﬂection of
the material and intellectual effort of many people,
will beuseful toour colleagues throughout theworld.
We dedicate it to them.
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